PMID- 32751391
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240329
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Electronic)
IS  - 1999-4923 (Linking)
VI  - 12
IP  - 8
DP  - 2020 Jul 29
TI  - Hydrolytic Degradability, Cell Tolerance and On-Demand Antibacterial Effect of 
      Electrospun Photodynamically Active Fibres.
LID - 10.3390/pharmaceutics12080711 [doi]
LID - 711
AB  - Photodynamically active fibres (PAFs) are a novel class of stimulus-sensitive 
      systems capable of triggering antibiotic-free antibacterial effect on-demand when 
      exposed to light. Despite their relevance in infection control, however, the 
      broad clinical applicability of PAFs has not yet been fully realised due to the 
      limited control in fibrous microstructure, cell tolerance and antibacterial 
      activity in the physiologic environment. We addressed this challenge by creating 
      semicrystalline electrospun fibres with varying content of 
      poly[(l-lactide)-co-(glycolide)] (PLGA), poly(epsilon-caprolactone) (PCL) and methylene 
      blue (MB), whereby the effect of polymer morphology, fibre composition and 
      photosensitiser (PS) uptake on wet state fibre behaviour and functions was 
      studied. The presence of crystalline domains and PS-polymer secondary 
      interactions proved key to accomplishing long-lasting fibrous microstructure, 
      controlled mass loss and controlled MB release profiles (37  degrees C, pH 7.4, 8 weeks). 
      PAFs with equivalent PLGA:PCL weight ratio successfully promoted attachment and 
      proliferation of L929 cells over a 7-day culture with and without light 
      activation, while triggering up to 2.5 and 4 log reduction in E. coli and S. 
      mutans viability, respectively. These results support the therapeutic 
      applicability of PAFs for frequently encountered bacterial infections, opening up 
      new opportunities in photodynamic fibrous systems with integrated wound healing 
      and infection control capabilities.
FAU - Contreras, Amy
AU  - Contreras A
AD  - Institute of Medical and Biological Engineering, University of Leeds, Leeds LS2 
      9JT, UK.
FAU - Raxworthy, Michael J
AU  - Raxworthy MJ
AD  - Institute of Medical and Biological Engineering, University of Leeds, Leeds LS2 
      9JT, UK.
AD  - Neotherix Ltd., The Hiscox Building, Peasholme Green, York YO1 7PR, UK.
FAU - Wood, Simon
AU  - Wood S
AD  - School of Dentistry, St. James's University Hospital, University of Leeds, Leeds 
      LS9 7TF, UK.
FAU - Tronci, Giuseppe
AU  - Tronci G
AUID- ORCID: 0000-0002-9426-4220
AD  - School of Dentistry, St. James's University Hospital, University of Leeds, Leeds 
      LS9 7TF, UK.
AD  - Clothworkers Centre for Textile Materials Innovation for Healthcare, School of 
      Design, University of Leeds, Leeds LS2 9JT, UK.
LA  - eng
GR  - EP/L014823/1/EPSRC/
PT  - Journal Article
DEP - 20200729
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC7465204
OTO - NOTNLM
OT  - antibacterial photodynamic effect
OT  - cytotoxicity
OT  - electrospun fibres
OT  - hydrolytic degradation
OT  - photosensitiser release
OT  - polymer morphology
COIS- The authors declare no conflict of interest. Michael J. Raxworthy is CEO of 
      Neotherix Ltd., participated in the conceptualization; methodology; validation; 
      formal analysis; resources; writing-review and editing; supervision; project 
      administration and funding acquisition of the manuscript. Neotherix Ltd. had a 
      role in the design of the study; in the collection, analyses or interpretation of 
      data; in the writing of the manuscript, or in the decision to publish the 
      results.
EDAT- 2020/08/06 06:00
MHDA- 2020/08/06 06:01
PMCR- 2020/08/01
CRDT- 2020/08/06 06:00
PHST- 2020/07/02 00:00 [received]
PHST- 2020/07/22 00:00 [revised]
PHST- 2020/07/24 00:00 [accepted]
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2020/08/06 06:01 [medline]
PHST- 2020/08/01 00:00 [pmc-release]
AID - pharmaceutics12080711 [pii]
AID - pharmaceutics-12-00711 [pii]
AID - 10.3390/pharmaceutics12080711 [doi]
PST - epublish
SO  - Pharmaceutics. 2020 Jul 29;12(8):711. doi: 10.3390/pharmaceutics12080711.